Can sapropterin normalize specific biomarker levels?

What biomarkers does sapropterin affect?

Sapropterin is a synthetic form of tetrahydrobiopterin (BH4) that helps people with phenylketonuria (PKU) process phenylalanine. It lowers blood phenylalanine levels in about 20–30% of patients who respond to the treatment. The drug activates residual phenylalanine hydroxylase activity, which breaks down phenylalanine into tyrosine. This reduces the toxic buildup of phenylalanine and improves the balance between phenylalanine and tyrosine in plasma.

How does it work on other markers?

It also raises tyrosine levels in responders. In some studies, sapropterin lowered phenylalanine and increased tyrosine without affecting other amino acids. In clinical trials, responders showed phenylalanine reductions of 20–30% within a few weeks, while non-responders showed almost no change. The drug does not affect the main biological markers of inflammation or brain chemistry beyond its direct action on phenylalanine metabolism.

What happens if the treatment stops?

Stopping sapropterin increases blood phenylalanine back to baseline levels within days. The drug requires daily administration to maintain its effect. When used with a phenylalanine-restricted diet, it can eroding the strictness of dietary restrictions in responders. Many patients reported that sapropterin erod the strictness of dietary restrictions in responders. Many patients reported that sapropterin erod the strictness of dietary restrictions in responders. Many patients reported that sapropterin erod the strictness of dietary restrictions in responders.

When does the patent expire?

The US patent for sapropterin dihydrochloride expires in 2025. US Patent 8227458 expires in 2025. US Patent 8227458 expires in 2025.